United States

Analyst Research Report Snapshot


Erytech Pharma SA (ERYP) - Financial Analysis Review






18 Mar 2014





Companies referenced:


Available for Immediate Download

Erytech Pharma SA (ERYP) - Financial Analysis Review Summary ERYtech Pharma (ERYtech) is a bio-pharmaceutical company providing innovative cancer therapies. Its product, ERY-ASP, which is in phase III development, provides therapeutic solution to frail patients with acute leukaemia. ERYtech has developed ERY-ASP, an original and effective treatment that targets leukemia cells through starvation while significantly reducing the side effects for patients. GlobalData's Erytech Pharma SA (ERYP) - Financial Analysis Review provides a comprehensive insight into the company's history, business structure and operations. The report contains information on the company's key employees, key competitors and major products and services, as well as detailed financial ratios for the last 5 years. Erytech Pharma SA Key Recent Developments: Jan 27, 2014: ERYTECH gives feedback on its first Investor R&D Day and provides a financial and business update for Q4 2013 Dec 20, 2013: ERYTECH Announces the Decision of USPTO to Extend the Additional Exclusivity Period of Its Core Process Patent to Almost 4 Years Aug 28, 2013: ERYTECH business update and financial results for the first half of 2013 Feb 20, 2013: Erytech Pharma To Present Two Posters On L-Asparaginase At Acute Leukemia XIV Conference This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better. Scope - Business description - A detailed description of the company's operations and business divisions. - Company history - Progression of key events associated with the company. - Major products and services - A list of major products, services and brands of the company. - Key competitors - A list of key competitors to the company. - Key employees - A list of the key executives of the company. - Executive biographies - A brief summary of the executives' employment history. - Key operational heads - A list of personnel heading key departments/functions. - Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details. - Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Note: Some sections may be missing if data is unavailable for the company. Reasons to Buy - Gain key insights into the company for academic or business research purposes. Key elements such as detailed business description and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. - Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services. - Examine potential investment and acquisition targets with this report's detailed insight into the company's business, financial and operational performance. Financial ratios presented for major public companies in the report include; revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.